Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by CalifDreamingon Dec 14, 2010 1:48pm
531 Views
Post# 17844509

RE: RE: Happy Now

RE: RE: Happy NowGo sign up and read it yourself.  Access to Jennings research is free.
But since you aren't the brightest bulb in the pack, results are expected this week.
The conclusion is really bullish:
Conclusion. The Canaguaro block holds a tremendous amount of short-term upside. We 
believe the market is valuing in the success at Canaguaro as a +2,000 Bbl/d per well 
field. The initial test rate from the Lower Mirador was 2,225 Bbl/d; keep in mind the Upper 
Mirador is currently being tested and it held the majority of the Mirador net oil pay. As 
mentioned above, the Upper Mirador at Balay-1 produced +1,000 Bbl/d on natural flow. 
Assuming the Upper Mirador is as productive as at Balay-1, the Canaguay-1 well could 
produce at multiples more than 2,225 Bbl/d with an ESP installed, especially if the 
Mirador intervals are commingled.  If the average Canaguaro well produces at our I.P. 
estimate of 2,500 Bbl/d, then the Company has an ExNAV of US
.36/share, which 

increases to US
.55/share if we increase our I.P. estimate to 6,000 Bbl/d.

Bullboard Posts